timothy sykes logo
INBX Stock Whipsaws Higher As Ozekibart Data Fuels Bullish Targets Thumbnail
G Google News

INBX Stock Whipsaws Higher As Ozekibart Data Fuels Bullish Targets

BRYCE TUOHEY•UPDATED APR. 22, 2026, 11:32 AM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Inhibrx Biosciences Inc. stocks have been trading up by 32.04 percent amid highly positive sentiment from recent biotech developments.

Candlestick Chart

Live Update At 11:32:18 EDT: On Wednesday, April 22, 2026 Inhibrx Biosciences Inc. stock [NASDAQ: INBX] is trending up by 32.04%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

INBX has been trading like a biotech rollercoaster. Over the last few weeks, Inhibrx Biosciences Inc. ran from around $59 at the end of 2026/03 up into the mid‑$80s, then exploded to an intraday high above $155 on 2026/04/22 before closing the day at $111.02. That kind of range tells traders this is a momentum ticker, not a sleepy pharma name.

Under the hood, INBX is still a classic clinical‑stage story. The company generated only about $1.3M in revenue, yet carries a hefty price‑to‑sales ratio near 925. That means traders are paying almost $926 for every $1 of sales, purely on pipeline expectations. Gross margin sits at 100%, typical for a royalty or milestone‑driven revenue base, while profit margins are deeply negative as Inhibrx spends heavily on trials.

The balance sheet shows roughly $124.2M in cash at 2025/12/31 against about $104.7M in long‑term debt and total liabilities of $138.5M. With a current ratio of 3.9, INBX appears funded for near‑term work, but free cash flow of about ‑$30.1M last quarter reminds traders that future raises remain a real possibility. For active traders, that mix of strong cash, high burn, and headline‑driven spikes sets up a classic catalyst stock.

Why Traders Are Watching INBX Right Now

The latest clinical update is the main reason INBX is front and center on so many biotech screens. Inhibrx Biosciences released new interim Phase 1/2 data for ozekibart (INBRX‑109) combined with FOLFIRI in heavily pretreated metastatic colorectal cancer. Even in that tough population, the combo delivered a 20% objective response rate, 87% disease control, and a median progression‑free survival of 5.5 months, all with a safety profile the company describes as manageable.

For traders, that matters because heavily pretreated colorectal cancer is where drugs usually struggle. When INBX shows any meaningful objective responses there, it de‑risks the mechanism and strengthens the bull case for ozekibart. If these results translate into earlier‑line settings, the commercial potential grows fast.

INBX is not just sitting on early data. Management is lining up an FDA meeting in 2026/2H to start a first‑line registrational colorectal cancer trial for ozekibart. At the same time, Inhibrx Biosciences is pushing potential accelerated pathways in fourth‑line colorectal cancer and refractory Ewing sarcoma, giving the ticker multiple shots on goal.

Layer on top the fact that INBX has already filed a Biologics License Application for ozekibart in conventional chondrosarcoma after a positive registrational trial. That shifts the story from “pure pre‑clinical hype” into “near‑commercial pipeline.” Stifel’s new Buy rating and $150 price target reinforce that message, signaling that at least one major shop believes the recent data and BLA filing justify substantial upside from current levels. New coverage tends to bring fresh eyes and volume, which short‑term traders in INBX are already trying to ride.

More Breaking News

Conclusion

Put it all together and INBX looks like a high‑volatility biotech centered on one clear theme: clinical progress turning into regulatory milestones. Inhibrx Biosciences now has encouraging ozekibart data in metastatic colorectal cancer, a BLA in conventional chondrosarcoma, and a plan for an FDA meeting that could unlock a first‑line registrational trial. That gives traders a defined roadmap of catalysts rather than vague long‑term dreams.

Financially, Inhibrx Biosciences Inc. is still burning cash and trading at rich multiples, but that is standard in this niche. What matters for traders is whether the data flow keeps supporting the ozekibart story and whether INBX can maintain enough capital to reach key readouts and potential approvals without crushing dilution.

The recent intraday spike from the $80s to above $150 shows how fast sentiment can swing when strong news hits a thin‑float biotech. Active traders in INBX will focus on liquidity, pre‑market gaps, and daily range around each headline. As Tim Sykes likes to say, “Trade the news, not the hype — react to the price action, cut losses quickly, and never fall in love with a story.” As millionaire penny stock trader and teacher Tim Sykes, says, “You must adapt to the market; the market will not adapt to you.”. For INBX, that mindset is essential as the company pushes ozekibart toward the next major FDA decisions.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading INBX

Millionaire's
POV on INBX

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”